Castle Creek Biosciences
Exton, US · Founded 2018 · Delaware corporation · 25 employees on LinkedIn · 4 known investors
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
Founders & leadership
MG
Matthew GantzinPresident and Chief Executive Officer
DC
David ChuinFounder
MT
Michael Townsley
CJ
Christopher J. LarsoninFounder
RW
Rhea WilliamsinFounder
JS
Jude SullivanExecutive
DP
Darien ParhadExecutive
MD
Michael DerbyChief Executive Officer
TC
Timothy CunniffNamed on SEC filing
Board
MC
Matthew CrabtreeBoard director
DB
David BrillBoard director
JA
Jeffrey AroninBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$839.8M disclosed across 6 rounds · 2018–2025
▶$75MraisedFeb 2025 · 30 investors · BiotechnologyRule 506(b)
▶$75MraisedFeb 2025 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BrillDirector
- Matthew CrabtreeDirector
- Jeffrey AroninDirector
- Matthew GantzExecutive Officer, Director
- Patrick MorrisDirector
- Jude SullivanExecutive Officer
- Darien ParhadExecutive Officer
- Antonio GraciasDirector
- Offering amount
- $75M
- Amount sold
- $75M
- Sales commissions
- $2.8M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$112.8MraisedMay 2022 · 54 investors · BiotechnologyRule 506(b)
▶$112.8MraisedMay 2022 · 54 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark GrafDirector
- Matthew J. GantzExecutive Officer, Director
- W. Bradford MiddlekauffExecutive Officer
- Mary SpellmanExecutive Officer
- Jeffrey S. AroninDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Offering amount
- $112.8M
- Amount sold
- $112.8M
- Sales commissions
- $1.7M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$11.8MraisedFeb 2022 · 6 investors · BiotechnologyRule 506(b)
▶$11.8MraisedFeb 2022 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- W. Bradford MiddlekauffExecutive Officer
- Matthew J. GantzExecutive Officer, Director
- Mark GrafDirector
- Patrick J. MorrisDirector
- Antonio GraciasDirector
- Babar GhiasExecutive Officer
- Mary SpellmanExecutive Officer
- Offering amount
- $11.8M
- Amount sold
- $11.8M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$25MraisedJul 2021 · 36 investors · BiotechnologyRule 506(b)
▶$25MraisedJul 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew J. GantzExecutive Officer, Director
- Mary SpellmanExecutive Officer
- Gregory MacMichaelExecutive Officer
- Gregory WujekExecutive Officer
- Antonio GraciasDirector
- W. Bradford MiddlekauffExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Offering amount
- $25M
- Amount sold
- $25M
- Sales commissions
- $625K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$54.6MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$54.6MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey S. AroninDirector
- Gregory WujekExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Timothy M. CunniffDirector
- Antonio J. GraciasDirector
- Offering amount
- $54.6M
- Amount sold
- $54.6M
- Minimum investment
- $82.4K
- Sales commissions
- $710K
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$560.5MraisedOct 2018 · 19 investors · PharmaceuticalsRule 506(b)
▶$560.5MraisedOct 2018 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey AroninDirector
- Michael DerbyExecutive Officer, Director
- Antonio GraciasDirector
- Patrick MorrisExecutive Officer, Director
- Timothy CunniffDirector
- Offering amount
- $560.5M
- Amount sold
- $560.5M
- Sales commissions
- $1.2M
- Placement agents
- Octagon Capital Group, LLC
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Castle Creek Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Castle Creek Biosciences do?
- Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
- Who are Castle Creek Biosciences's investors?
- Castle Creek Biosciences's investors include Paragon Biosciences LLC, Valor Equity Partners, Fidelity Investments, Horizon.
- How much funding has Castle Creek Biosciences raised?
- Castle Creek Biosciences has disclosed $839.8M raised across 6 rounds.
- Where is Castle Creek Biosciences headquartered?
- Castle Creek Biosciences is headquartered in Exton, US.